Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Topotecan hydrochloride
Drug ID BADD_D02249
Description An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Indications and Usage For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
Marketing Status approved; investigational
ATC Code L01CE01
DrugBank ID DB01030
KEGG ID D02168
MeSH ID D019772
PubChem ID 60699
TTD Drug ID D0Z4XW
NDC Product Code 45963-615; 61187-001; 63323-762; 0078-0674; 29902-0001; 65129-1131; 16729-151; 55390-370
UNII 956S425ZCY
Synonyms Topotecan | 9-Dimethylaminomethyl-10-hydroxycamptothecin | 9 Dimethylaminomethyl 10 hydroxycamptothecin | Topotecan Hydrochloride | Hydrochloride, Topotecan | Nogitecan Hydrochloride | Hydrochloride, Nogitecan | Topotecan Monohydrochloride, (S)-Isomer | SK&F-104864-A | SK&F 104864 A | SK&F104864A | SKF-104864-A | SKF 104864 A | SKF104864A | Hycamtin | NSC-609699 | NSC 609699 | NSC609699 | Hycamtamine
Chemical Information
Molecular Formula C23H24ClN3O5
CAS Registry Number 119413-54-6
SMILES CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm16.16.02.001---
Nervous system disorder17.02.10.001---
Neuralgia17.02.07.005--
Neuropathy peripheral17.09.03.003---
Neutropenia01.02.03.004---
Pain08.01.08.004--
Pancytopenia01.03.03.003---
Paraesthesia17.02.06.005; 23.03.03.094--
Paresis17.01.04.008---
Pelvic pain07.01.06.012; 20.02.03.007; 21.10.01.001--
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pleural effusion22.05.02.002--
Pleuritic pain22.12.01.007--
Pneumonia11.01.09.003; 22.07.01.003---
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.001---
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rash maculo-papular23.03.13.004--
Respiratory failure14.01.04.003; 22.02.06.002--
Rhinitis11.01.13.004; 22.07.03.006--
Sepsis11.01.11.003--
Skin disorder23.03.03.007---
Stomatitis07.05.06.005--
Thrombocytopenia01.08.01.002---
Tumour pain16.32.03.003--
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages